|
|
|
|
|
|
|
|
June 30, 2017 | December 31, 2016 | ||||||
(In thousands) | |||||||
Cash and cash equivalents | $ | 48,181 | $ | 22,058 | |||
Long-term restricted cash equivalents | 6,336 | 6,336 | |||||
Total cash, cash equivalents and restricted cash equivalents | $ | 54,517 | $ | 28,394 |
|
June 30, 2017 | December 31, 2016 | ||||||
(Unaudited - In thousands) | |||||||
Equity Method: | |||||||
Partner companies | $ | 118,513 | $ | 154,219 | |||
Private equity funds | 445 | 447 | |||||
118,958 | 154,666 | ||||||
Cost Method: | |||||||
Other holdings | 2,687 | 2,112 | |||||
Private equity funds | 1,334 | 1,550 | |||||
4,021 | 3,662 | ||||||
Advances to partner companies | 25,050 | 25,142 | |||||
$ | 148,029 | $ | 183,470 |
|
|
Carrying Value | Fair Value Measurement at June 30, 2017 | |||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||
(Unaudited - In thousands) | ||||||||||||||||
Cash and cash equivalents | $ | 48,181 | $ | 48,181 | $ | — | $ | — | ||||||||
Long-term restricted cash equivalents | 6,336 | 6,336 | — | — | — | |||||||||||
Marketable securities—held-to-maturity: | ||||||||||||||||
Certificates of deposit | $ | 5,422 | $ | 5,422 | $ | — | $ | — | ||||||||
Total marketable securities | $ | 5,422 | $ | 5,422 | $ | — | $ | — |
Carrying Value | Fair Value Measurement at December 31, 2016 | ||||||||||||||
Level 1 | Level 2 | Level 3 | |||||||||||||
(Unaudited - In thousands) | |||||||||||||||
Cash and cash equivalents | $ | 22,058 | $ | 22,058 | $ | — | $ | — | |||||||
Long-term restricted cash equivalents | 6,336 | 6,336 | — | — | |||||||||||
Marketable securities—held-to-maturity: | |||||||||||||||
Certificates of deposit | $ | 15,686 | $ | 15,686 | $ | — | $ | — | |||||||
Total marketable securities | $ | 15,686 | $ | 15,686 | $ | — | $ | — |
|
|
Three months ended June 30, | Six months ended June 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
(Unaudited - In thousands) | |||||||||||||||
General and administrative expense | $ | 351 | $ | 467 | $ | 246 | $ | 1,275 | |||||||
$ | 351 | $ | 467 | $ | 246 | $ | 1,275 |
1) | performance-based; |
2) | service-based. |
|
|
Partner Company | Safeguard Primary Ownership as of June 30, 2017 | Accounting Method | |
AdvantEdge Healthcare Solutions, Inc. | 40.1% | Equity | |
Aktana, Inc. | 24.5% | Equity | |
Apprenda, Inc. | 29.4% | Equity | |
Brickwork | 20.3% | Equity | |
Cask Data, Inc. | 31.3% | Equity | |
CloudMine, Inc. | 47.3% | Equity | |
Clutch Holdings, Inc. | 42.8% | Equity | |
Full Measure Education, Inc. | 42.3% | Equity | |
Good Start Genetics, Inc. | 29.6% | Equity | |
Hoopla Software, Inc. | 25.5% | Equity | |
InfoBionic, Inc. | 39.7% | Equity | |
Lumesis, Inc. | 44.1% | Equity | |
MediaMath, Inc. | 20.5% | Equity | |
meQuilibrium | 31.5% | Equity | |
Moxe Health Corporation | 32.4% | Equity | |
NovaSom, Inc. | 31.7% | Equity | |
Pneuron | 35.4% | Equity | |
Prognos (fka Medivo, Inc.) | 35.2% | Equity | |
Propeller Health, Inc. | 24.0% | Equity | |
QuanticMind, Inc. | 23.2% | Equity | |
Sonobi, Inc. | 21.6% | Equity | |
Spongecell, Inc. | 23.0% | Equity | |
Syapse, Inc. | 26.2% | Equity | |
T-REX Group, Inc. | 23.6% | Equity | |
Transactis, Inc. | 24.0% | Equity | |
Trice Medical, Inc. | 24.9% | Equity | |
WebLinc, Inc. | 38.0% | Equity | |
Zipnosis, Inc. | 25.4% | Equity |
|
|
|
|
June 30, 2017 | December 31, 2016 | ||||||
(In thousands) | |||||||
Cash and cash equivalents | $ | 48,181 | $ | 22,058 | |||
Long-term restricted cash equivalents | 6,336 | 6,336 | |||||
Total cash, cash equivalents and restricted cash equivalents | $ | 54,517 | $ | 28,394 |
|
June 30, 2017 | December 31, 2016 | ||||||
(Unaudited - In thousands) | |||||||
Equity Method: | |||||||
Partner companies | $ | 118,513 | $ | 154,219 | |||
Private equity funds | 445 | 447 | |||||
118,958 | 154,666 | ||||||
Cost Method: | |||||||
Other holdings | 2,687 | 2,112 | |||||
Private equity funds | 1,334 | 1,550 | |||||
4,021 | 3,662 | ||||||
Advances to partner companies | 25,050 | 25,142 | |||||
$ | 148,029 | $ | 183,470 |
|
Carrying Value | Fair Value Measurement at June 30, 2017 | |||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||
(Unaudited - In thousands) | ||||||||||||||||
Cash and cash equivalents | $ | 48,181 | $ | 48,181 | $ | — | $ | — | ||||||||
Long-term restricted cash equivalents | 6,336 | 6,336 | — | — | — | |||||||||||
Marketable securities—held-to-maturity: | ||||||||||||||||
Certificates of deposit | $ | 5,422 | $ | 5,422 | $ | — | $ | — | ||||||||
Total marketable securities | $ | 5,422 | $ | 5,422 | $ | — | $ | — |
Carrying Value | Fair Value Measurement at December 31, 2016 | ||||||||||||||
Level 1 | Level 2 | Level 3 | |||||||||||||
(Unaudited - In thousands) | |||||||||||||||
Cash and cash equivalents | $ | 22,058 | $ | 22,058 | $ | — | $ | — | |||||||
Long-term restricted cash equivalents | 6,336 | 6,336 | — | — | |||||||||||
Marketable securities—held-to-maturity: | |||||||||||||||
Certificates of deposit | $ | 15,686 | $ | 15,686 | $ | — | $ | — | |||||||
Total marketable securities | $ | 15,686 | $ | 15,686 | $ | — | $ | — |
|
Three months ended June 30, | Six months ended June 30, | ||||||||||||||
2017 | 2016 | 2017 | 2016 | ||||||||||||
(Unaudited - In thousands) | |||||||||||||||
General and administrative expense | $ | 351 | $ | 467 | $ | 246 | $ | 1,275 | |||||||
$ | 351 | $ | 467 | $ | 246 | $ | 1,275 |
1) | performance-based; |
2) | service-based. |
|
Partner Company | Safeguard Primary Ownership as of June 30, 2017 | Accounting Method | |
AdvantEdge Healthcare Solutions, Inc. | 40.1% | Equity | |
Aktana, Inc. | 24.5% | Equity | |
Apprenda, Inc. | 29.4% | Equity | |
Brickwork | 20.3% | Equity | |
Cask Data, Inc. | 31.3% | Equity | |
CloudMine, Inc. | 47.3% | Equity | |
Clutch Holdings, Inc. | 42.8% | Equity | |
Full Measure Education, Inc. | 42.3% | Equity | |
Good Start Genetics, Inc. | 29.6% | Equity | |
Hoopla Software, Inc. | 25.5% | Equity | |
InfoBionic, Inc. | 39.7% | Equity | |
Lumesis, Inc. | 44.1% | Equity | |
MediaMath, Inc. | 20.5% | Equity | |
meQuilibrium | 31.5% | Equity | |
Moxe Health Corporation | 32.4% | Equity | |
NovaSom, Inc. | 31.7% | Equity | |
Pneuron | 35.4% | Equity | |
Prognos (fka Medivo, Inc.) | 35.2% | Equity | |
Propeller Health, Inc. | 24.0% | Equity | |
QuanticMind, Inc. | 23.2% | Equity | |
Sonobi, Inc. | 21.6% | Equity | |
Spongecell, Inc. | 23.0% | Equity | |
Syapse, Inc. | 26.2% | Equity | |
T-REX Group, Inc. | 23.6% | Equity | |
Transactis, Inc. | 24.0% | Equity | |
Trice Medical, Inc. | 24.9% | Equity | |
WebLinc, Inc. | 38.0% | Equity | |
Zipnosis, Inc. | 25.4% | Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|